Triple therapy for acute deep thrombophlebitis.
Therapy for patients with extensive thrombophlebitis is ofter inadequate with available methods. The reluctance of most physicians in private practice to use streptokinase or urokinase is understandable when one considers the cost, hospitalization, length of stay and risks involved. This article discusses a unique and previously unreported mode of drug therapy in these patients, consisting of a combination of drugs designed to combine the antithrombotic and thrombusantipropagating effects of warfarin, the anti-inflammatory effect of trypsin-chymotrypsin enzymes, and the antiplatelet aggregating, antiadhesion, and possible enhanced fibrinolytic effects of aspirin with added buffered protection (Ascriptin A/D). This treatment program has been a safe, efficient, economical, and highly effective one for a very costly, common, and disabling disease. It therefore fulfills the ideal criteria for any form of therapy, provided one is knowledgable of its content, and adheres to its contraindications as well as to the basic application of the drugs involved. It is hoped that further investigations along these lines will continue until an ideal solution is reached. Although this is a preliminary report, this study will continue in its present form, and will be expanded to include a series of patients on the aspirin-enzyme combination without the use of warfarin.
D000208:Acute Disease; D000328:Adult; D000368:Aged; D000893:Anti-Inflammatory Agents; D000925:Anticoagulants; D001241:Aspirin / Q000627:therapeutic use; D002918:Chymotrypsin / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006801:Humans; D008297:Male; D008875:Middle Aged; D010690:Phlebography; D013924:Thrombophlebitis / Q000188:drug therapy / Q000191:economics / Q000628:therapy*; D014357:Trypsin / Q000627:therapeutic use; D014859:Warfarin / Q000627:therapeutic use
D000893:Anti-Inflammatory Agents; D000925:Anticoagulants; D014859:Warfarin; D002918:Chymotrypsin; D014357:Trypsin; D001241:Aspirin